On December 4-5, SenzaGen was attending BioFIT in Lille, France. BioFIT is a business development meeting with focus on early stage innovations including pre-clinical stage assets. We met with CROs and life science companies from all over Europe in search of screening tools at pre-clinical stage. Read more about Biofit here: https://www.biofit-event.com
SenzaGen is attending the Society of Toxicology (STC) of Canada’s 50th Annual Symposium, on December 10-12 in Toronto, Canada. Joshua Schmidt, Business Development Director Americas at SenzaGen, will participate at the symposium and present the poster: GARD – Assessing Skin and Respiratory Sensitizers in vitro using a genomics-based platform.
STC is a non-profit association whose objectives are to promote the acquisition, facilitate the dissemination, and encourage the utilization of knowledge in the science of toxicology. They support continuing education and excellence in research through its Annual Symposium, which provides a venue for members and international experts to present the latest advances in experimental and regulatory toxicology.
To book a meeting, please email Joshua Schmidt at:
joshua.schmidt (a) senzagen.com
Hope to see you there!
For more information about the symposium, please visit:
Dr Andy Forreryd, scientist at SenzaGen, is one of three speakers at the Human Safety Seminar organised by Eurofins BioPharma Product Testing Munich where he will be presenting the GARD® platform for skin and respiratory sensitization. The seminar will be hosted on November 29 at the new laboratory and office building of Eurofins Munich, Robert-Koch-Straße 3a in Planegg near Munich, Germany.
The topics for the seminar are:
- In vitro Methods to test for Endocrine Disrupting Properties
- In vitro Skin sensitization – Challenges to Overcome
- Eye Irritation ex vivo and in vitro methods – Current status
- GARD® platform, genomic test for skin and respiratory sensitization with potency classification
- New Developments in Genotoxicity Testing for Chemicals, Cosmetics and Pharmaceuticals – in vitro and in vivo Comet Assay
For more information and registration:
SenzaGen is attending the Biocompatibility Summit in Barcelona this week, on November 27-29. The summit will address updates and changes to the ISO 10993 standards and Biocompatibility for devices with a focus on Risk Mitigation, Chemical Characterisation and Practical Implementation.
Come meet our colleagues and specialists Rose Marie Jenvert, Medical Device Project Manager and Joshua Schmidt, Business Development Director – Americas there!
To book a meeting, please email them at:
rose-marie.jenvert (a) senzagen.com
joshua.schmidt (a) senzagen.com
SenzaGen is attending the SFT conference (Société Française de Toxicologie) in Lille, France, on November 27-28. The conference is the French Society of Toxicology’s annual meeting and SenzaGen is present with a poster: GARD® – Genomic Allergen Rapid Detection, In vitro Safety Assessment of Skin and Respiratory Sensitizers using a Genomics Based Platform. Our French distribution partner Eurosafe is also present with a booth where you can get more information about GARD® and about our collaboration with Eurosafe.
Live presentations at Financial Meetings Øresund’s event “Sverige fortsatt starkt för Life Science?”
SenzaGen’s CEO Anki Malmborg Hager will share the inspiring story of SenzaGen and how SenzaGen’s platform GARD®, a group of tests for animal-free safety testing, can replace animal tests using genomics in test tubes to assess whether chemicals are allergenic or not.
Watch live presentation here:
SenzaGen’s CEO Anki Malmborg Hager will speak at Financial Meetings Øresund, November 19, 2018.
As a speakers in the event “Sverige fortsatt starkt för Life Science? Anki will share the inspiring story of SenzaGen and how SenzaGen’s platform GARD®, a group of tests for animal-free safety testing, can replace animal tests using genomics in test tubes to assess whether chemicals are allergenic or not.
For more information and registration,
In vitro testing for Respiratory Sensitizers using a genomic biomarker signature and the GARD™ technology platform
The presentations on 4 and 5 December 2018, will give insight into the latest in vitro technology for identifying respiratory sensitizers using human dendritic-like cell lines and genomics. A thorough explanation of the GARD™ platform will be covered as well as its versatility and reliability for safety assessment applicable to all industries. Sensitization testing with GARD™ is based on functional genomics.
The presentation will cover:
- Development of the genomic-based GARD™ test platform for skin sensitization hazard, potency classification, and now also respiratory sensitization.
- Dendritic cells – why they are also relevant for respiratory sensitization.
- Gene mapping – what genes are in the assay, and how are they relevant for sensitization.
- How GARD™ can discriminate between skin and respiratory sensitization and why this is relevant.
- Update on the development of the SenzaGen R&D pipeline including GARD™ for materials – testing medical devices, GARD™ for proteins – classification of protein sensitizers, GARD™ for mixtures – assessment of complex formulations and Unknown or Variable Composition UVCBs.
Next generation in vitro skin and respiratory sensitization testing using genomics with GARD™
The GARD™ platform is a versatile in vitro testing strategy which currently consist of three assays targeting two toxicological endpoints: skin sensitization (GARDskin & GARDpotency) and respiratory sensitization (GARDair). These assays make use of unique genomic biomarker signatures comprising genes involved in pathways known to be immunologically relevant to the sensitization process. Supported by modern technologies for pattern recognition, the large informational content provided by this approach enable for mechanism-of-action based decisions, which becomes evident in a consistently high predictive accuracy
Don’t miss the opportunity to learn more from our researchers.
Register by clicking on any of the links below.
Tue 4 Dec 2018, 15:00 CET
Wed 5 Dec 2018, 13:00 EST